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ABSTRACT
Fungal infections are an important cause 
of morbidity and mortality in neonatal 
intensive care units (NICUs). The identifi-
cation of specific risk factors supports pre-
vention of candidemia in neonates. Effec-
tive prophylactic strategies have recently 
become available, but the identification 
and adequate management of high-risk in-
fants is still a priority. Prior colonization is 
a key risk factor for candidemia. For this 
reason, surveillance studies to monitor in-
cidence, species distribution, and antifun-
gal susceptibility profiles, are mandatory. 
Among 520 infants admitted to our NICU 
between January 2013 and December 
2014, 472 (90.77%) were included in the 
study. Forty-eight out of 472 (10.17%) pa-
tients tested positive for Candida spp. (C.), 
at least on one occasion. All the colonized 
patients tested positive for the rectal swab, 
whereas 7 patients also tested positive for 
the nasal swab. Fifteen out of 472 patients 
(3.18%) had more than one positive rec-
tal or nasal swab during their NICU stay. 
Moreover, 9 out of 15 patients tested nega-
tive at the first sampling, suggesting they 
acquired Candida spp. during their stay. 
Twenty-five of forty-eight (52.1%) colo-
nized patients carried C.albicans and 15/48 
(31.25%) C.parapsilosis. We identified as 
risk factors for Candida spp. colonization: 
antibiotic therapy, parenteral nutrition, 
the use of a central venous catheter, and 
nasogastric tube. Our experience suggests 
that effective microbiological surveillance 
can allow for implementing proper, effec-
tive and timely control measures in a high-
risk setting.
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INTRODUCTION
Fungal infections are an important cause 
of increased morbidity and mortality in 
infants admitted to neonatal intensive care 
units (NICUs). In very low birth weight 
(VLBW) infants Candida (C.) albicans is 
the third most common cause of neona-
tal late onset sepsis (LOS). (1) The over-
all incidence of candidemia in NICUs is 
increasing because of longer survival and 
more invasive procedures related with the 
intensive care of extremely preterm in-
fants. According to a multicentric study 
carried out in Virginia, the rate of noso-
comial bloodstream infection due to Can-
dida species in babies admitted to NICU 
is reported as 12.3/1,000 admissions and 
0.64/1,000 patient days. (2) Many factors 
account for the high risk of systemic fun-
gal infections (SFI) in preterm infants in 
the NICU. They include: prior antibiotic 
exposure, hyper alimentation, use of in-
travenous fat emulsions and endotracheal 
intubation. (3,4) Prior colonization is a key 
risk factor for candidemia and it has been 
identified as the first step in pathogenesis 
of invasive candidiasis. (5) Colonization of 
the infant occurs early in life and this is af-
fected by a variety of common practices in 
the NICU. About 60% of VLBW neonates 
are colonized during their first month in 
the NICU, (6) with a peak incidence dur-
ing the 2nd and 3rd week of life. About 
85% of them acquire the fungus horizon-
tally (nosocomial acquisition) vs. 15% 
who are colonized vertically (i.e. from the 
mother). It is very difficult to reconstruct 
transmission on the ward. (8) 
The interaction between colonization 
and risk factors has been investigated ex-
perimentally and clinically. Bendel et al. 
(9) have shown that dissemination takes 
place when dexamethasone is given to rats 
treated with antibiotics and colonized by 
fungi. A specific role for hyperglycaemia, 
colonization of the CVC (central venous 
catheter), number of colonized sites and 
candiduria, in determining the progres-
sion to dissemination and SFI has been 
shown as well. (4)
Colonization of neonates with Candida in 
the NICU is a problem that requires atten-
tion, especially in patients with identified 
risk factors. A similar approach is needed 
as with other dangerous colonizations, 
such as Meticillin Resistan Staphylococcus 
Aureus. (10,11) In fact, the combination of 
“nearly endemic” presence of Candida col-
onization in neonates with other risks fac-
tors, increases the risk of SFI. Prevention 
of candidemia in neonates is supported by 
identification and adequate management 
of specific risk factors, including low birth 
weight, use of invasive devices, prolonged 
hospitalization and use of broad-spectrum 
antimicrobial agents. Effective prophylac-
tic strategies have recently become avail-
able, but the identification of the best pos-
sible strategies to manage high-risk infants 
is still a priority. Previous experience with 
the circulation of pathogenic microorgan-
isms in the NICU, suggests that for fungi 
it is also mandatory to conduct surveil-
lance studies to monitor incidence, species 
distribution, and antifungal susceptibility 
profiles. (12)
To assess the epidemiology of Candida 
spp. colonization in hospitalized neonates 
in our setting, we performed a prospec-
tive cohort study at the tertiary NICU of 
the University Hospital ‘‘Paolo Giaccone’’, 
Palermo, Italy.
MATERIALS AND METHODS
Among 520 infants admitted to the NICU 
between January 2013 and December 
2014, 472 (90.77%) were included in the 
study. Major clinical characteristics of 
infants were: malformations (101/472; 
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21.4%), prematurity (163/466; 35%) and 
surgical procedures (21/472; 4.4%). Other 
important part of infants were outborn 
admissions (195/469; 41.6%). Th e NICU 
includes one intensive care room, consist-
ing of 8 cot spaces, and one intermediate 
care room, with a further 8 cot spaces. Th e 
average nurse to patient ratio is 1:3 and 1:4 
in the two sections, respectively. Th e NICU 
ward is open to parents for 2 hours in the 
morning and 4 hours in the aft ernoon, so 
that they can be progressively involved in 
the general care of their child under the 
guidance and supervision of staff . Early 
breastfeeding is supported.
During the study period we collected 
weekly nasal and rectal swabs from each 
neonate hospitalized in the NICU. Inclu-
sion criteria were: admission to NICU be-
tween January 2013 and December 2014, a 
hospital stay of at least 48 hours, complete 
demographic and clinical data and the col-
lection of at least one nasal swab. Moreo-
ver, demographic and clinical data ex-
pected to aff ect Candida colonization were 
recorded for each patient. On admission, 
demographic characteristics, gestational 
age, birth weight, born in this or another 
NICU condition, delivery type, APGAR 
score and comorbid conditions were re-
corded. During the NICU stay, qualitative 
and quantitative data were collected for 
the following variables: presence of central 
vascular access devices, endotracheal intu-
bation and mechanical ventilation, nasal 
continuous positive airway pressure (nC-
PAP), peripheral catheters, type of feeding 
(i.e. parenteral nutrition, enteral nutrition 
with oral suction or gavage, breast milk, 
formula), need and timing of surgery, an-
tibacterial and antifungal drug therapy, 
length of stay and survival status at dis-
charge.
Nasal and rectal swabs were inoculated 
on Sabouraud agar dextrose (Oxoid, Bas-
ingstoke, UK) and incubated at 30°C for 
4 days. Th e Candida isolates were identi-
fi ed by standard procedures, i.e. morphol-
ogy on Corn meal agar plates, germ-tube 
test (GTT) in fetal calf serum, Candida 
chromogenic agar (ChromAgar Candida, 
Laboratorios Conda; Madrid, Spain), and 
biochemical analysis with the API® 20C 
AUX identifi cation system (bioMérieux, 
Marcy-l’Etoile, France). 
Infants were categorized as colonized by 
Candida spp. when at least one nasal swab 
tested positive. We evaluated Candida spp. 
colonization rate and assessed the related 
risk factors.
All data recording and statistical analyses 
were performed by EpiInfo (CDC soft -
ware), and Fisher’s exact test was used to 
assess risk factors, assuming as statistically 
signifi cant a p value < 0.05.
RESULTS 
In this two-year study we enrolled 472 
out of 520 patients admitted to the NICU, 
for which we collected complete micro-
biological, clinical and demographic data. 
Th e main features of the population under 
study are summarized in Table 1.  Forty-
eight out of 472 (10.17%) patients tested 
positive for Candida spp. at least on one 
occasion. In particular, 25 patients tested 
positive for C. albicans, 15 for C. parapsilo-
sis, 6 for C. glabrata, 1 for C. guilliermondi 
and 1 patient tested positive both for C. 
albicans and C. parapsilosis. All colonized 
patients had a positive rectal swab, whereas 
7 patients also had a positive nasal swab. 
Fift een out of 472 patients (3.18%) had 
more than one positive rectal or nasal swab 
during their NICU stay. Moreover, 9 out of 
15 patients tested negative at the fi rst sam-
pling, suggesting they acquired Candida 
spp. during their stay. 
Th e reported carriage rate was 
8.73% (11/126) in the fi rst semester, 
10.74%(13/121) in the second, 8.04% 
(9/112) in the third and 13.27% (15/113) 
in the fourth, as shown in Figure 1.
Figure 1. Carriage rate for semesters of 
study.
Demographic and clinical characteristics 
of the population under study are summa-
rized in Table 1. 
A total of 296/472 (62.7%) enrolled pa-
tients received at least one antibiotic 
during their hospitalization and 38/471 
(8.07%) received at least one antifungal. 
36/471 (7.64%) patients received fl ucona-
zole prophylaxis, among these we found 3 
colonization cases (3/36, 8.33%). In infants 
who did not received fl uconazole proph-
ylaxis we found 45 colonization cases 
(45/436, 10.32%). No statistically signifi -
cant diff erence was found between these 
two groups (p-value=0.49).
We investigated the association between 
Candida colonization and clinical and de-
mographic data. Table 2 summarizes data 
about risk factors. Administration of anti-
biotic therapy, use of a CVC and parenteral 
nutrition were signifi cantly associated with 
Candida colonization. 
No infection cases of any kind were report-
ed during the study. 
DISCUSSION
Th e results of this study clearly suggest that 
eff ective microbiological surveillance can 
help maintain the quality of care provided. 
Th e microbiological surveillance of Can-
dida spp. colonization allowed us to iden-
tify risk factors, to monitor groups of high-
risk patients and  to implement eff ective 
and timely control measures in this high 
risk setting. Th e prevalence of colonization 
by Candida spp. in our NICU is near 10% 
and it is lower than other studies reported. 
(4, 9,13) However, we underline that the 
population involved and the patients en-
rolled in our study diff er in some measure 
from those of others NICUs. Our patients 
have a higher gestational age and birth 
weight (respectively 37.1 weeks and 2795 
grams) when compared to other study 
populations. Th ese demographic data, in-
volving less measures of care by healthcare 
workers, could partially explain the lower 
colonization rate. Moreover, no infection 
cases were reported during the study.
According to prior studies, the rectum 
is the most common site of coloniza-
tion. C.albicans and C.parapsilosis are 
the two most common organisms. (14-
17) Twenty-fi ve of forty-eight (52.1%) 
colonized patients carried C.albicans and 
15/48 (31.25%) C.parapsilosis. Th e rate 
of C.parapsilosis colonization is modestly 
higher than data reported in other paedi-
atric units (2,18,19), so it could be consid-
ered an important and distinctive feature 
of our NICU, requiring deeper analysis. 
We identifi ed as risk factors for Candida 
spp. Colonization: antibiotic therapy, par-
enteral nutrition, the use of CVCs, and 
nasogastric tubes. Our data are clearly in 
agreement with the current knowledge in 
this fi eld. Saiman et al. (4) reported that 
the use of third generation cephalosporins 
was associated with both C.albicans  and 
C.parapsilosis colonization. Moreover, the 
insertion of central venous catheters or use 
of intravenous lipids were found to be risk 
factors for C.albicans.
By contrast, no signifi cant association 
with gestational age and birth weight was 
reported in our study. Until now, data we 
have collected do not indicate a statistically 
signifi cant association with these variables 
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Table 1. Demographic and clinical characteristics of 472 neonates included in the study.
Variable
Male, No. (%) 280/472 (59,4)
Caesarean section, No. (%) 268/472 (58,9)
Born in onother NICU , No. (%) 195/472 (41.6)
Preterm, No. (%) 162/472 (34.3)
Malformations, No. (%) 101/472 (21.4)
Twins, No. (%) 41/472 (9.1)
Gestational age in weeks, median (IQR) 38 (35-39)
Birth weight in grams, median (IQR) 2940 (2280-3300)
5’ APGAR score <8, No. (%) 46/472 (9.75)
Days of hospital stay, median (IQR) 12 (9-20)
Surgical intervention, No. (%) 21/472 (4.4)
Breastfeeding, No. (%) 304/472 (64.5)
Formula, No. (%) 452/ 472 (95.8)
Invasive devices
Peripheral catheter, No. (%) 366/472 (77.5) 
Central catheter, No. (%) 126/471 (26.8)
nCPAP, No. (%) 80/472 (16.9)
Endotracheal tube, No. (%) 57/472 (12.1)
Parenteral nutrition, No. (%) 354/472 (75)
Antimicrobial therapy
Ampicillin/sulbactam, No, (%) 286 (60.6)
Amoxicillin/clavulanic acid, No, (%) 17 (3.60) 
Aminoglycosides, No, (%) 256 (54.2) 
Cephalosporins, No, (%) 13 (2.8)
Glycopeptides, No, (%) 12 (2.5)
Fluconazole, No, (%) 36 (7.6)
Micafungin, No, (%) 3 (0.6)
Metronidazole, No, (%) 2 (0.4)
IQR, interquartile range; nCPAP, nasal continuous positive airway pressure.
Table 2. Risk factors for Candida colonization
Risk factors Colonized n=48
No.(%)
Not colonized n=424
No.(%)
RR
( 95% CI)
P-value
(Fisher exact test)
Antibiotic  therapy 43 (89.6) 253 (59.7) 1.14 (1.07-1.19) <0.001*
Fluconazole prophylaxis 3 (6.2) 33 (7.8) 0.98 (0.88-1.08) 0.49
CVC 23 (47.9) 103 (24.3) 1.13 ( 1.04-1.24) <0.001*
Parenteral nutrition 43 (89.6) 311 (73.3) 1.09 (1.03-1.15) <0.001*
Nasogastric tube 19 (39.6) 114 (26.9) 1.07 (0.98-1.15) 0.15
Born in onother NICU 21 (47.7) 173 (41.1) 0.98 (0.93-1.05) 0.37
Male gender 30 (59) 249 (62.5) 1.01 (0.95-1.08) 0.38
Gestational age, weeks
Median (IQR)
38 (36-39) 38 Not suitable 0.50
Caesarean section 28 (59.6) 239 (58.8) 1.01 (0.94-1.07) 0.52
Birth weight, grams
Median (IQR)
3070 (2110-3470) 2910 (2290-3290) Not suitable 0.55
CVC, central venous catheter; CI, 95% confidence interval; IQR, interquartile range; RR, Relative risk; 95% *= significant p-value
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(p-value ≥ 0.05). Most likely this data is re-
lated to inherent features of our population 
and to the limited numbers of cases. 
Antifungal prophylaxis with fluconazole 
proved to be useful in the management of 
fungal colonization and infections in adult 
immunocompromised patients and effec-
tive in terms of reduction of candidemia 
rates. For these reasons it has been intro-
duced in the routine prevention of invasive 
fungal diseases in other clinical contexts 
such as neonatology, targeted to preterm 
infants characterized by an immature im-
mune system. (20- 22) 
In our study, 7.64% of enrolled patients 
received fluconazole prophylactically. (17) 
There was no statistically significant differ-
ence between the treated and not treated 
groups in terms of colonization rate. This 
data could be partially related to the low 
number of treated patients in our study 
population and it emphasises the need for 
a continuous surveillance study. We un-
derline that this study is still in place at our 
NICU. It is our intent to carry on a similar 
analysis in the next few years to more pre-
cisely asses the connection with all these 
risk factors.
Our understanding of the epidemiology 
of Candida spp. has grown appreciably 
over the past years. (19) In this context, we 
underline the effectiveness of a microbio-
logical surveillance plan. It is important to 
define the local epidemiology and to moni-
tor rapid changes in the rates of infection, 
potential risk factors, and emerging patho-
gen species. Continuous and close surveil-
lance plays a key role in the management 
of high-risk wards and it could support the 
development of rational prevention and 
control measures to achieve better quality 
of care.
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